You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
|
|---|---|
| Published in |
Arthritis Research & Therapy, June 2016
|
| DOI | 10.1186/s13075-016-1022-1 |
| Pubmed ID | |
| Authors |
Gianfranco Ferraccioli, Barbara Tolusso, Elisa Gremese |
| Abstract |
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 3 | 33% |
| Student > Doctoral Student | 1 | 11% |
| Other | 1 | 11% |
| Researcher | 1 | 11% |
| Professor > Associate Professor | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 2 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 56% |
| Neuroscience | 1 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
| Unknown | 2 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2016.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Arthritis Research & Therapy
#3,132
of 3,381 outputs
Outputs of similar age
#309,482
of 353,816 outputs
Outputs of similar age from Arthritis Research & Therapy
#53
of 57 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,816 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.